Mark is the Chief Executive Officer at Aculeus Therapeutics and the former Chief Scientific Officer at Amplia Therapeutics. He was the Biology Leader of the CRC for Cancer Therapeutics (CTx) program that discovered AMP945 and AMP886. After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on drug discovery and development in several therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark worked at the Peter MacCallum Cancer Centre between 2008 and 2018 in various roles for CTx), first as Head of the Translational Cancer Biology Laboratory and later as Director of Translational Cancer Biology. In his role as a lead scientist, Mark and his team were involved in the PRMT5 program that was licensed by CTx to MSD, in 2016 and the Chromatin-Modifying Enzyme programs licensed to Pfizer Inc in 2018.